Want to see SGMT full AI Analyst Report?
SGMT Stock Chart & Stats
$6.47
-$0.58(-10.41%)
At close: 4:00 PM EST
$6.47
-$0.58(-10.41%)
Day’s Range― - ―
52-Week Range$4.50 - $11.41
Previous CloseN/A
Volume1.06M
Average Volume (3M)1.19M
Market Cap
$455.21M
Enterprise Value$176.17M
Total Cash (Recent Filing)$104.54M
Total Debt (Recent Filing)$39.00K
Price to Earnings (P/E)―
Beta2.93
Next Earnings
Aug 19, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.35
Shares Outstanding61,184,315
10 Day Avg. Volume1,796,878
30 Day Avg. Volume1,186,629
Financial Highlights & Ratios
PEG Ratio-0.42
Price to Book (P/B)1.72
Price to Sales (P/S)0.00
P/FCF Ratio-4.19
Enterprise Value/Market Cap0.39
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.82
Forecast
1Y Price Target
$28.44Price Target Upside339.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.2
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Strong Balance SheetExtremely low leverage and sizable equity provide Sagimet durable financial flexibility to fund multi-year clinical programs, pursue partnerships, and absorb development setbacks without heavy interest burdens. This balance-sheet strength preserves optionality across several years of execution risk.
Major $164.5M Equity Raise To Fund PipelineThe ~ $164.5M net proceeds materially extend runway and fund planned U.S. Phase 3 work, Phase 2 progression and IND activities. This capital reduces near-term financing risk and enables multi-stage clinical execution, making the company less likely to pause programs for lack of funding.
Clinical And Regulatory Progress For DenifanstatPhase 3 success in China and NMPA NDA acceptance constitute durable de-risking for the lead asset. Regulatory traction and positive clinical data increase commercialization options, strengthen IP and partnering prospects, and improve the likelihood of sustained program funding and strategic alliances.
Bears Say
Persistent Negative Operating Cash Flow And FCFConsistently negative operating cash flow and material FCF deficits show the business is not self-sustaining. Over the medium term this necessitates continued external funding, increases dependency on capital markets, and raises execution risk if financing conditions tighten.
Minimal Revenue And Substantial Operating LossesVery limited current revenue and ongoing large operating losses mean profitability is distant and the model remains pre-commercial. Long-term value depends on successful clinical outcomes and commercialization, making near-term fundamentals highly binary and execution-dependent.
Dilution Risk From Reliance On Equity FinancingsWhile the equity raise improves runway, it also evidences reliance on dilutive financings to support development. If trials expand or setbacks occur, repeat financings could further dilute shareholders and constrain long-term per-share returns despite operational progress.
Sagimet Biosciences, Inc. Class A News
SGMT FAQ
What was Sagimet Biosciences, Inc. Class A’s price range in the past 12 months?
Sagimet Biosciences, Inc. Class A lowest stock price was $4.50 and its highest was $11.41 in the past 12 months.
What is Sagimet Biosciences, Inc. Class A’s market cap?
Sagimet Biosciences, Inc. Class A’s market cap is $455.21M.
When is Sagimet Biosciences, Inc. Class A’s upcoming earnings report date?
Sagimet Biosciences, Inc. Class A’s upcoming earnings report date is Aug 19, 2026 which is in 40 days.
How were Sagimet Biosciences, Inc. Class A’s earnings last quarter?
Sagimet Biosciences, Inc. Class A released its earnings results on May 12, 2026. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.371 by $0.041.
Is Sagimet Biosciences, Inc. Class A overvalued?
According to Wall Street analysts Sagimet Biosciences, Inc. Class A’s price is currently Undervalued.
Does Sagimet Biosciences, Inc. Class A pay dividends?
Sagimet Biosciences, Inc. Class A does not currently pay dividends.
What is Sagimet Biosciences, Inc. Class A’s EPS estimate?
Sagimet Biosciences, Inc. Class A’s EPS estimate is -0.25.
How many shares outstanding does Sagimet Biosciences, Inc. Class A have?
Sagimet Biosciences, Inc. Class A has 61,184,315 shares outstanding.
What happened to Sagimet Biosciences, Inc. Class A’s price movement after its last earnings report?
Sagimet Biosciences, Inc. Class A reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.371. Following the earnings report the stock price went down -0.52%.
Which hedge fund is a major shareholder of Sagimet Biosciences, Inc. Class A?
Currently, no hedge funds are holding shares in SGMT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sagimet Biosciences, Inc. Class A Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.44 (339.64% Upside)
$28.44 (339.64% Upside)
Blogger Sentiment
Bullish
SGMT Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 3.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 5.0%
Last 30 Days ▼ 5.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-18.68%
12-Months-Change
Fundamentals
Return on Equity
-37.57%
Trailing 12-Months
Asset Growth
-26.28%
Trailing 12-Months
Company Description
Sagimet Biosciences, Inc. Class A
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
SGMT Stock 12 Month Forecast
Average Price Target
$28.44
▲(339.64% Upside)
Technical Analysis
Codexis
―
Cabaletta Bio
―
Black Diamond Therapeutics
―
Atea Pharmaceuticals
―
Entrada Therapeutics Inc
―
Ownership Overview
5.49% Insiders
6.72% Mutual Funds
0.18% Other Institutional Investors
78.39% Public Companies and Individual Investors